𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer

✍ Scribed by John A. Conti; Nancy E. Kemeny; Leonard B. Saltz; A. McKenzie André; Dennis D. Grossano; Joseph R. Bertino

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
527 KB
Volume
75
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A simplified regimen of weekly high dose
A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma
✍ Tsai-Shen Yang; Kuan-Cheng Hsu; Jy-Ming Chiang; Reiping Tang; Jinn-Shium Chen; C 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 2 views

## BACKGROUND. Reports of in vitro experiments in colorectal carcinoma cells suggest that prolonged cellular exposure to 5-fluorouracil (5-FU) combined with relatively low concentrations of leucovorin (LV) provides optimal enhancement of 5-FU efficacy. In this study, a simplified regimen of weekly

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Hepatic chemoembolization combined with
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma : A Southwest Oncology Group pilot trial
✍ Cynthia Gail Leichman; Joth R. Jacobson; Manuel Modiano; John R. Daniels; Mark M 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

## BACKGROUND. Rates of response to systemic chemotherapy among patients with advanced colorectal carcinoma rarely exceed 25-30%, and complete responses are rare. The liver is the most common site of metastasis; however, regional therapies have not improved survival rates. The Southwest Oncology Gr